Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma

M. Vlachová, J. Gregorová, P. Vychytilová-Faltejsková, NA. Gabło, L. Radová, L. Pospíšilová, M. Almáši, M. Štork, Z. Knechtová, J. Minařík, T. Popková, T. Jelínek, R. Hájek, L. Pour, L. Říhová, S. Ševčíková

. 2022 ; 23 (23) : . [pub] 20221125

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032583

Extramedullary multiple myeloma (EMD) is an aggressive disease; malignant plasma cells lose their dependence in the bone marrow microenvironment and migrate into tissues. EMD is a negative prognostic factor of survival. Using flow cytometry and next-generation sequencing, we aimed to identify antigens and microRNAs (miRNAs) involved in EMD pathogenesis. Flow cytometry analysis revealed significant differences in the level of clonal plasma cells between MM and EMD patients, while the expression of CD markers was comparable between these two groups. Further, miR-26a-5p and miR-30e-5p were found to be significantly down-regulated in EMD compared to MM. Based on the expression of miR-26a-5p, we were able to distinguish these two groups of patients with high sensitivity and specificity. In addition, the involvement of deregulated miRNAs in cell cycle regulation, ubiquitin-mediated proteolysis and signaling pathways associated with infections or neurological disorders was observed using GO and KEGG pathways enrichment analysis. Subsequently, a correlation between the expression of analyzed miRNAs and the levels of CD molecules was observed. Finally, clinicopathological characteristics as well as CD antigens associated with the prognosis of MM and EMD patients were identified. Altogether, we identified several molecules possibly involved in the transformation of MM into EMD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032583
003      
CZ-PrNML
005      
20230131150735.0
007      
ta
008      
230120s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms232314765 $2 doi
035    __
$a (PubMed)36499093
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vlachová, Monika $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
245    10
$a Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma / $c M. Vlachová, J. Gregorová, P. Vychytilová-Faltejsková, NA. Gabło, L. Radová, L. Pospíšilová, M. Almáši, M. Štork, Z. Knechtová, J. Minařík, T. Popková, T. Jelínek, R. Hájek, L. Pour, L. Říhová, S. Ševčíková
520    9_
$a Extramedullary multiple myeloma (EMD) is an aggressive disease; malignant plasma cells lose their dependence in the bone marrow microenvironment and migrate into tissues. EMD is a negative prognostic factor of survival. Using flow cytometry and next-generation sequencing, we aimed to identify antigens and microRNAs (miRNAs) involved in EMD pathogenesis. Flow cytometry analysis revealed significant differences in the level of clonal plasma cells between MM and EMD patients, while the expression of CD markers was comparable between these two groups. Further, miR-26a-5p and miR-30e-5p were found to be significantly down-regulated in EMD compared to MM. Based on the expression of miR-26a-5p, we were able to distinguish these two groups of patients with high sensitivity and specificity. In addition, the involvement of deregulated miRNAs in cell cycle regulation, ubiquitin-mediated proteolysis and signaling pathways associated with infections or neurological disorders was observed using GO and KEGG pathways enrichment analysis. Subsequently, a correlation between the expression of analyzed miRNAs and the levels of CD molecules was observed. Finally, clinicopathological characteristics as well as CD antigens associated with the prognosis of MM and EMD patients were identified. Altogether, we identified several molecules possibly involved in the transformation of MM into EMD.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x genetika $7 D009101
650    12
$a mikro RNA $x genetika $7 D035683
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a nádorové mikroprostředí $7 D059016
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gregorová, Jana $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Vychytilová-Faltejsková, Petra $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000338813536
700    1_
$a Gabło, Natalia Anna $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Radová, Lenka $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/000000018103148X
700    1_
$a Pospíšilová, Lenka $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Almáši, Martina $u Department of Clinical Hematology, University Hospital Brno, 625 00 Brno, Czech Republic
700    1_
$a Štork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000270728537
700    1_
$a Knechtová, Zdeňka $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, 625 00 Brno, Czech Republic
700    1_
$a Minařík, Jiří $u Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000030513326X
700    1_
$a Popková, Tereza $u Department of Hematooncology, University Hospital Ostrava, Ostrava, and Faculty of Medicine, University Ostrava, 708 00 Ostrava, Czech Republic
700    1_
$a Jelínek, Tomáš $u Department of Hematooncology, University Hospital Ostrava, Ostrava, and Faculty of Medicine, University Ostrava, 708 00 Ostrava, Czech Republic $1 https://orcid.org/0000000254679253
700    1_
$a Hájek, Roman $u Department of Hematooncology, University Hospital Ostrava, Ostrava, and Faculty of Medicine, University Ostrava, 708 00 Ostrava, Czech Republic
700    1_
$a Pour, Luděk $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, 625 00 Brno, Czech Republic
700    1_
$a Říhová, Lucie $u Department of Clinical Hematology, University Hospital Brno, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000336398463
700    1_
$a Ševčíková, Sabina $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000271946771
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 23, č. 23 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36499093 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131150731 $b ABA008
999    __
$a ok $b bmc $g 1891385 $s 1183918
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 23 $c 23 $e 20221125 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace